Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2026Diabetes

2170-P: Association of Newer Glucose-Lowering Drugs with Incident Parkinsonian Disorders in Older Adults with REM Sleep Behavior Disorder and Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPareeta KotechaJBJIANG BIANSGSerena Jingchuan Guo

Discussion

Loading...

Member takes

Overview

Randomized trial evaluated incident risk of Parkinsonian disorders in older adults with iRBD and T2D, suggesting class-dependent risk.

Key Points

  • This study aims to assess the risk of Parkinson's disease and related disorders in older adults with isolated REM sleep behavior disorder and type 2 diabetes based on glucose-lowering drug class.
  • Conducted a target trial emulation using retrospective active-comparator design through Medicare claims.
  • Included new users of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors among individuals aged 65+ with iRBD and T2D.
  • Utilized Cox proportional hazards models with stabilized inverse probability weighting to estimate hazard ratios.
  • GLP-1RA users showed significantly lower risk of PD (HR 0.02; 95% CI, 0.001 - 0.20) compared to DPP-4i users.
  • SGLT-2i use also showed lower risk of PD (HR 0.03; 95% CI, 0.001 - 0.97) compared to DPP-4i users.
  • No significant differences were found for Lewy body dementia or between GLP-1RA and SGLT-2i users.

Cite This Study

Kotecha et al. (2026) studied this question.

synapsesocial.com/papers/6a250b2d7def13d035e1b228https://doi.org/10.2337/db26-2170-p
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1750-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Incident Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes2024
  2. 2Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study2024 · 10 citations
  3. 3Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation2025 · 1 citations
  4. 4916-P: SGLT2 Inhibitors and Parkinson’s Disease (PD) Risk in Older Populations with Type 2 Diabetes (T2D)2024 · 2 citations
  5. 5Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes2024 · 8 citations